Novexel SA, a privately held French company that develops antibacterial and antifungal products, has licensed a beta-lactamase inhibitor, NXL104, to a subsidiary of Forest Laboratories Inc of the United States for €75 million plus milestone payments of potentially €75 million and “low double-digit” royalties on sales in North America.
